Primary Progressive AphasiaSymptoms, Doctors, Treatments, Advances & More
Primary Progressive Aphasia Overview
Learn About Primary Progressive Aphasia
- Primary progressive aphasia
- Aphasia, primary progressive
- PPA
- Primary progressive aphasia syndrome
Johns Hopkins Outpatient Center
Dr. Argye Hillis is a professor of Neurology, with joint faculty appointments in Physical Medicine and Rehabilitation and in Cognitive Science. She is also the Sheikh Khalifa Stroke Institute Professor of Acute Stroke Diagnoses and Management. Prior to medical training and neurology residency, Dr. Hillis worked as a speech-language pathologist, and conducted clinical research focusing on understanding and treating aphasia and hemispatial neglect. She has brought these areas of experience to impact on her clinical research in neurology, which involves cognitive and neuroimaging studies of aphasia and hemispatial neglect due to acute stroke and focal dementias. She has published extensively on these topics in journals and textbooks. Dr. Hillis is Associate Editor of Stroke and has served as Associate editor of Brain, Annals of Neurology, Aphasiology, American Journal of Speech-Language Pathology, Neurocase, Cognitive Neuropsychology, and Language and Cognitive Processes and served as co-Editor and Chief of Behavioral Neurology. Dr. Hillis serves as the Executive Vice Chair of the Department of Neurology and the Director of the Cerebrovascular Division of Neurology at Johns Hopkins. Dr. Hillis is rated as an Elite provider by MediFind in the treatment of Primary Progressive Aphasia. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Primary Progressive Aphasia, Stroke, Frontotemporal Dementia, Thrombectomy, and Gastrostomy. Dr. Hillis is board certified in American Board Of Psychiatry And Neurology.
Memory And Aging Center
Dr. Maria Luisa Gorno-Tempini is a neurologist at the UCSF Memory and Aging Center. Her goal in patient care is to use state-of the-art cognitive and imaging techniques to diagnose and treat neurological disorders. She places a particular emphasis on managing dementia and neurodegenerative disorders. Gorno-Tempini's main research interest is progressive aphasia, impaired ability to speak or understand language. Gorno-Tempini completed her medical degree and specialty training in neurology in Italy, with a focus on behavioral neurology. She worked for three years in the Functional Imaging Laboratory at University College London, where she also earned a doctorate in imaging neuroscience. Dr. Gorno is rated as an Elite provider by MediFind in the treatment of Primary Progressive Aphasia. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Primary Progressive Aphasia, Dementia, Frontotemporal Dementia, and Developmental Reading Disorder. Dr. Gorno is currently accepting new patients.
Memory And Aging Center
Dr. William Seeley works at the UCSF Memory and Aging Center. He cares for patients with neurodegenerative diseases, such as Alzheimer's disease and frontotemporal dementia (FTD). In 2011, Seeley was named a MacArthur Foundation Fellow for his research on understanding FTD and other neurodegenerative diseases. His research focuses on why dementias target specific nerve cell populations. The goal is to discover what makes brain tissues susceptible or resistant to degeneration and to translate these findings into new treatments. Seeley earned his medical degree at UCSF, where he also completed an internship in internal medicine. He completed a residency in neurology at the Massachusetts General and Brigham and Women's hospitals in Boston, followed by a fellowship in behavioral neurology at UCSF. Dr. Seeley is rated as an Elite provider by MediFind in the treatment of Primary Progressive Aphasia. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Frontotemporal Dementia, Dementia, Primary Progressive Aphasia, and Alzheimer's Disease. Dr. Seeley is board certified in American Board Of Psychiatry And Neurology., Neurology. Dr. Seeley is currently accepting new patients.
Summary: The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Summary: The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


